RNA is an essential molecule in cellular biology, translating genetic
instructions encoded in DNA into the production of the proteins that enable
cells to function. However, as protein production is also a central factor in
most human diseases and disorders, RNA-based therapeutics have long been
thought to hold the potential to treat a range of problems where conventional
drug-based treatments cannot offer much help. The field has been slow to
develop, however, with initial high hopes being dented by the sheer complexity
of the effort and the need to better understand the variability of gene
expression in cells.
Over the past year, there has been a resurgence of interest in this new
field of biotech healthcare, with two RNA-based treatments approved as human
therapeutics as of 2014. RNA-based drugs for a range of conditions including
genetic disorders, cancer and infectious disease are being developed based on
the mechanism of RNA interference, which is used to silence the expression of
defective or over-expressed genes.
Extending the repertoire of RNA-based therapeutics, an even newer platform
based on messenger RNA (mRNA) molecules is now emerging. Specific mRNA
sequences injected intramuscular or intravenously can act as therapeutic
agents through the patient’s own cells, translating them into the corresponding
proteins that deliver the therapeutic effect. Unlike treatments aimed at
changing DNA directly, RNA-based therapeutics do not cause permanent changes to
the cell’s genome and so can be increased or discontinued as necessary.
Advances in basic RNA science, synthesis technology and in vivo delivery are
combining to enable a new generation of RNA-based drugs that can attenuate the
abundance of natural proteins, or allow for the in vivo production of
optimized, therapeutic proteins. Working in collaboration with large
pharmaceutical companies and academia, several private companies that aim to
offer RNA-based treatments have been launched. We expect this field of
healthcare to increasingly challenge conventional pharmaceuticals in forging
new treatments for difficult diseases in the next few years.
0 comments:
Post a Comment